Detalhe da pesquisa
1.
Cross-Reactivity of Antibodies to Rituximab with Other Therapeutic Anti-CD20 Antibodies.
J Immunol
; 212(4): 529-533, 2024 Feb 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38149924
2.
Clinical and humoral responses after SARS-CoV-2 breakthrough infections in patients with immunosuppressants.
J Allergy Clin Immunol
; 2024 May 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-38763170
3.
Ocrelizumab Concentration Is a Good Predictor of SARS-CoV-2 Vaccination Response in Patients with Multiple Sclerosis.
Ann Neurol
; 93(1): 103-108, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36250739
4.
Suppressed IgG4 class switching in dupilumab- and TNF inhibitor-treated patients after mRNA vaccination.
Allergy
; 2024 Mar 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-38439527
5.
T cell activation markers CD38 and HLA-DR indicative of non-seroconversion in anti-CD20-treated patients with multiple sclerosis following SARS-CoV-2 mRNA vaccination.
J Neurol Neurosurg Psychiatry
; 2024 Mar 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-38548324
6.
Extended interval dosing of ocrelizumab modifies the repopulation of B cells without altering the clinical efficacy in multiple sclerosis.
J Neuroinflammation
; 20(1): 215, 2023 Sep 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-37752582
7.
Disease activity in patients with immune-mediated inflammatory diseases after SARS-CoV-2 vaccinations.
J Autoimmun
; 135: 102984, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36621174
8.
Association of age and inflammatory disease activity in the pivotal natalizumab clinical trials in relapsing-remitting multiple sclerosis.
J Neurol Neurosurg Psychiatry
; 94(10): 792-799, 2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37173129
9.
Decrease of natalizumab drug levels after switching from intravenous to subcutaneous administration in patients with multiple sclerosis.
J Neurol Neurosurg Psychiatry
; 94(6): 482-486, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36639226
10.
SARS-CoV-2 omicron breakthrough infections in patients with multiple sclerosis.
J Neurol Neurosurg Psychiatry
; 94(4): 280-283, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36564175
11.
Ocrelizumab concentration and antidrug antibodies are associated with B-cell count in multiple sclerosis.
J Neurol Neurosurg Psychiatry
; 94(6): 487-493, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36693720
12.
Primary SARS-CoV-2 infection in patients with immune-mediated inflammatory diseases: long-term humoral immune responses and effects on disease activity.
BMC Infect Dis
; 23(1): 332, 2023 May 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-37198536
13.
Risk factors associated with short-term adverse events after SARS-CoV-2 vaccination in patients with immune-mediated inflammatory diseases.
BMC Med
; 20(1): 100, 2022 03 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-35236350
14.
Breakthrough infections with the SARS-CoV-2 omicron (B.1.1.529) variant in patients with immune-mediated inflammatory diseases.
Ann Rheum Dis
; 81(12): 1757-1766, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-36357161
15.
Persistence of seroconversion at 6 months following primary immunisation in patients with immune-mediated inflammatory diseases.
Ann Rheum Dis
; 82(6): 883-885, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36720583
16.
Vaccination responses in B-cell-depleted multiple sclerosis patients: The role of drug pharmacokinetics.
Eur J Neurol
; 29(11): 3137-3138, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-35997630
17.
Serum neurofilaments as candidate biomarkers of natalizumab associated progressive multifocal leukoencephalopathy.
Ann Neurol
; 86(2): 322-324, 2019 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-31192473
18.
The association between blood MxA mRNA and long-term disease activity in early multiple sclerosis.
Front Neurol
; 13: 907245, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36062003
19.
Longitudinal SARS-CoV-2 humoral response in MS patients with and without SARS-CoV-2 infection prior to vaccination.
Front Neurol
; 13: 1032830, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36438945
20.
Longitudinal T-Cell Responses After a Third SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis on Ocrelizumab or Fingolimod.
Neurol Neuroimmunol Neuroinflamm
; 9(4)2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35523569